Track topics on Twitter Track topics that are important to you
Ascendis Pharma (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced financial results for the quarter ended September 30, 2018 and released preliminary phase 1 data for TransCon CNP. As quoted in the press release: “To support our vision for sustainable growth, we are creating a diversified … Continued
The post Ascendis Pharma Reports Third Quarter 2018 Financial Results appeared first on Investing News Network.
Original Article: Ascendis Pharma Reports Third Quarter 2018 Financial ResultsNEXT ARTICLE
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...